Amarin - The Science Of Lipid Therapy (Seite 6)

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 73.606.426 von Kopflaus am 03.04.23 16:28:43

Amarin

Um in der Alex Denner Sprache zu bleiben: Rom wurde auch nicht an einem Tag erbaut!

Meiner Meinung nach, müssen wir 6-12 Monate Geduld aufbringen, jedoch kann Pfizer blitzschnell zuschlagen, was ich nicht glaube, dazu ist der Aktienkurs viel zu niedrig für eine zweistellige Übernahme!

[Kopflaus]

Antwort auf Beitrag Nr.: 73.496.428 von Magnetfeldfredy am 17.03.23 11:57:23

Bisher wurden noch keine Werte für die Aktionäre geschaffen.
Kommen hoffentlich bald wieder bessere Tage!

[Magnetfeldfredy]

Amarin

AMRN Amarin Corporation released the following statement: "Since joining the company two weeks ago, the new Amarin board has rolled up its sleeves and begun the hard work of creating value for shareholders.We continue to believe that Amarin has tremendous potential. Our drug has the potential to both improve cardiovascular outcomes for patients and create significant savings for payors - a unique proposition for a drug. Unfortunately for society, in our view, not enough patients worldwide are taking VASCEPA. Although the new board has begun its work with urgency, we appreciate that Rome was not built in a day. The work to be done is substantial. We will proceed diligently and thoughtfully as shareholders deserve our best efforts. To the hard-working employees at the company, we understand that any change, in this case a new board, can create uncertainty. We want employees to rest assured that we intend to create a great culture of success at Amarin where employees have the tools to succeed and are rewarded for their performance. We remain confident in our ability to leverage VASCEPA's clinically important drug profile to unlock tremendous value for shareholders. With shareholders on the board, we believe Amarin's best days are ahead."

Read more at:
https://thefly.com/n.php?id=3681079

[lobberland]

Antwort auf Beitrag Nr.: 73.492.225 von nionus am 16.03.23 19:04:39

Ja, ich wäre auch schon seit längerem ready 🙄

[nionus]

https://amarincorp.com/news-and-media/reconstituted-amarin-b…

[Kopflaus]

Antwort auf Beitrag Nr.: 73.469.608 von derogher am 14.03.23 10:43:17

Wer weß was da gespielkt wird!
Bei uns 5 % Plus derzeit entsprechend 1,50 €
Bei Verkauf nur 1,43 €, also Spreed von 4 !/2 Prozent

[derogher]

habe ich etwas verpasst?

1.5500-0.0400 (-2.52%)
At close: March 13 04:00PM EDT
1.8400 +0.29 (+18.71%)
Pre-Market: 05:07AM EDT

[nionus]

https://amarincorp.com/news-and-media/amarin-highlights-new-…

[nionus]

Denner räumt jetzt auf:
https://amarincorp.com/news-and-media/amarin-announces-board…

[Magnetfeldfredy]

Amarin

Geil mein Freund, sehr geil, go Alex go:

Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
4

Tue, February 28, 2023 at 4:39 PM GMT+1
In this article:

AMRN
+13.8587%
Watchlist

Significant Event | 1dyahoo plus badge
Amarin And Csl Seqirus Announce Exclusive License And Distribution Agreement To Commercialize Vazkepa In Australia And New Zealand

Sarissa honored to have received 100 million more votes than Amarin board

GREENWICH, Conn., February 28, 2023--(BUSINESS WIRE)--Sarissa Capital Management LP today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):

Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin board. Our estimate is that up to nearly 80% of shareholder votes were in support of Sarissa. As Amarin’s largest shareholder, we are grateful for the opportunity to remake Amarin for the benefit of all shareholders.

Vascepa, the foundation on which Amarin is built, is a tremendous drug that is compelling for patients and payors – a unique proposition for a drug. While there is a lot of work to be done, we remain confident in our ability to leverage Vascepa’s rare and highly beneficial profile to unlock tremendous value for all shareholders.

LET’S GET TO WORK AND FINALLY BEGIN RUNNING AMARIN FOR THE BENEFIT OF ALL SHAREHOLDERS!

Additional Information

Sarissa Capital Management LP ("Sarissa Capital"), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the "Company") at the general meeting of the Company for the election of Sarissa Capital’s slate of highly-qualified nominees (the "General Meeting"). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.

The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov and at www.freeamarin.com. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital’s proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: [phone]).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005961/en/

Contacts

Dayna Packes
Sarissa Capital Management LP
[e-mail]
#FreeAmarin